BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35609360)

  • 1. Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.
    Kim T; Ahn JS; Son MH; Novitzky-Basso I; Yi SY; Ahn SY; Jung SH; Yang DH; Lee JJ; Choi SH; Lee JY; Moon JH; Sohn SK; Kim HJ; Zhang Z; Kim DDH
    Leuk Res; 2022 Jul; 118():106858. PubMed ID: 35609360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
    Zhang SJ; Rampal R; Manshouri T; Patel J; Mensah N; Kayserian A; Hricik T; Heguy A; Hedvat C; Gönen M; Kantarjian H; Levine RL; Abdel-Wahab O; Verstovsek S
    Blood; 2012 May; 119(19):4480-5. PubMed ID: 22431577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
    Liu YC; Illar GM; Bailey NG
    J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
    Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
    Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
    Li B; Mascarenhas JO; Rampal RK
    Curr Hematol Malig Rep; 2018 Dec; 13(6):588-595. PubMed ID: 30353413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of clinical characteristics of bone marrow proliferative tumor progression to acute myeloid leukemia.
    Li Y; Zhang XY; Han J; Wang L
    Cancer Biomark; 2018; 23(4):469-472. PubMed ID: 30452397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Yang C; Zhang Q; Tang X; Wang B; Guan M; Tang G; Wu Z
    Epigenomics; 2022 Apr; 14(7):391-403. PubMed ID: 35259923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
    Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
    Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genomic profiling reveals molecular subsets of
    Johnson SM; Haberberger J; Galeotti J; Ramkissoon L; Coombs CC; Richardson DR; Foster MC; Duncan D; Montgomery ND; Ferguson NL; Zeidner JF
    Leuk Lymphoma; 2024 Feb; 65(2):209-218. PubMed ID: 37921062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
    Pasca S; Chifotides HT; Verstovsek S; Bose P
    Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel.
    Tan J; Chow YP; Zainul Abidin N; Chang KM; Selvaratnam V; Tumian NR; Poh YM; Veerakumarasivam A; Laffan MA; Wong CL
    BMC Med Genomics; 2022 Jan; 15(1):10. PubMed ID: 35033063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
    Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
    Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What are the molecular mechanisms driving the switch from MPNs to leukemia?
    Wang X; Hoffman R
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101254. PubMed ID: 33762108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-existence of mutations in myeloproliferative neoplasms and their clinical significance: a prognostic approach.
    Homaei Hadad E; Pezeshki SMS; Shahrabi S; Saki Malehi A; Saki N
    Expert Rev Hematol; 2020 Nov; 13(11):1289-1301. PubMed ID: 32886563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent insights regarding the molecular basis of myeloproliferative neoplasms.
    Jang MA; Choi CW
    Korean J Intern Med; 2020 Jan; 35(1):1-11. PubMed ID: 31778606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms.
    Kalmer M; Pannen K; Lemanzyk R; Wirths C; Baumeister J; Maurer A; Kricheldorf K; Schifflers J; Gezer D; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
    Ann Hematol; 2022 Dec; 101(12):2655-2663. PubMed ID: 36269400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.